Publications by authors named "Elizabeth Masters"

Claim this Profile
C
Crossing borders: the need for empirical evidence of real-world evidence transportability in oncology.
Caitlin Clunie-O'Connor, Per-Olof Thuresson, Elizabeth Masters, Aliki Taylor, Mats Rosenlund

J Comp Eff Res· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient experience and unmet needs in high-risk nonmuscle-invasive bladder cancer: Insights from qualitative interviews and a cross-sectional survey.
Lewis Kopenhafer, Allison Thompson, Jane Chang, Slaven Sikirica, Elizabeth T Masters

Urol Oncol· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modeling Challenges in Cost-Effectiveness Analysis of First-Line Immuno-Oncology Therapies in Non-small Cell Lung Cancer: A Systematic Literature Review.
Thitima Kongnakorn, Grammati Sarri, Andreas Freitag, Kinga Marczell, Paulina Kazmierska, Elizabeth Masters

Pharmacoeconomics· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health care resource utilization and costs associated with advanced or metastatic nonsmall cell lung cancer in the United States.
Xinke Zhang, Daniel C Beachler, Elizabeth Masters, Frank Liu, Mo Yang

J Manag Care Spec Pharm· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment Outcomes of High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) in Real-World Evidence (RWE) Studies: Systematic Literature Review (SLR).
Mihaela Georgiana Musat, Christina Soeun Kwon, Elizabeth Masters, Slaven Sikirica, Debduth B Pijush

Clinicoecon Outcomes Res· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world treatment patterns and outcomes in PD-L1-positive non-small cell lung cancer.
Xinke Zhang, Richard W DeClue, Lisa Herms, Mo Yang, Vivek Pawar, Elizabeth T Masters

Immunotherapy· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Cost-Effectiveness of Lorlatinib Versus Chemotherapy as a Second- or Third-Line Treatment in Anaplastic Lymphoma Kinase (ALK)-Positive Non-small-cell Lung Cancer in Sweden.
Fredrik O L Nilsson, Sandra T Asanin, Elizabeth T Masters, Laura Iadeluca, Chrissy Almond

Pharmacoeconomics· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Retrospective Observational Study of ALK-Inhibitor Therapy Sequencing and Outcomes in Patients with ALK-Positive Non-small Cell Lung Cancer.
David M Waterhouse, Janet L Espirito, Marc D Chioda, Bismark Baidoo, Jack Mardekian, Elizabeth T Masters

Drugs Real World Outcomes· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Humanistic and Economic Burden of Non-Muscle Invasive Bladder Cancer: Results of Two Systematic Literature Reviews.
Lauren J Lee, Christina S Kwon, Anna Forsythe, Carla M Mamolo, Elizabeth T Masters

Clinicoecon Outcomes Res· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment Sequencing in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer in Japan: A Real-World Observational Study.
Yasushi Goto, Nobuyuki Yamamoto, Elizabeth T Masters, Hironori Kikkawa, Jack Mardekian

Adv Ther· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of lorlatinib on patient-reported outcomes in patients with advanced ALK-positive or ROS1-positive non-small cell lung cancer.
Solange Peters, Alice T Shaw, Benjamin Besse, Enriqueta Felip, Benjamin J Solomon, Elizabeth T Masters

Lung Cancer· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Natural Language Processing-Identified Problem Opioid Use and Its Associated Health Care Costs.
Elizabeth T Masters, Arvind Ramaprasan, Jack Mardekian, Roy E Palmer, David E Gross

J Pain Palliat Care Pharmacother· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Systematic review of sequencing of ALK inhibitors in -positive non-small-cell lung cancer.
Stephanie M Barrows, Kelly Wright, Catherine Copley-Merriman, James A Kaye, Marc Chioda, Elizabeth T Masters

Lung Cancer (Auckl)· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Results of PROFILE 1029, a Phase III Comparison of First-Line Crizotinib versus Chemotherapy in East Asian Patients with ALK-Positive Advanced Non-Small Cell Lung Cancer.
Yi-Long Wu, Shun Lu, You Lu, Jianying Zhou, Yuan-Kai Shi, Elizabeth T Masters

J Thorac Oncol· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost of opioid medication abuse with and without tampering in the USA.
Jeffrey Vietri, Elizabeth T Masters, Alexandra I Barsdorf, Jack Mardekian

Clinicoecon Outcomes Res· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Use and Outcomes of ALK-Positive Crizotinib-Treated Metastatic NSCLC in US Community Oncology Practices: A Retrospective Observational Study.
Craig Reynolds, Elizabeth T Masters, Jenny Black-Shinn, Marley Boyd, Jack Mardekian

J Clin Med· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Educational intervention for physicians to address the risk of opioid abuse.
Margaret K Pasquale, Richard L Sheer, Jack Mardekian, Elizabeth T Masters, Nick C Patel

J Opioid Manag· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enhancing Risk Assessment in Patients Receiving Chronic Opioid Analgesic Therapy Using Natural Language Processing.
Irina V Haller, Colleen M Renier, Mitch Juusola, Paul Hitz, William Steffen, Elizabeth T Masters

Pain Med· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient-reported health-related quality of life, work productivity, and activity impairment during treatment with ALO-02 (extended-release oxycodone and sequestered naltrexone) for moderate-to-severe chronic low back pain.
Arnold J Weil, Elizabeth T Masters, Alexandra I Barsdorf, Almasa Bass, Glenn Pixton

Health Qual Life Outcomes· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A systematic review of the effectiveness of policies restricting access to pregabalin.
Brett R Stacey, Jonathan Liss, Regina Behar, Alesia Sadosky, Bruce Parsons, Elizabeth T Masters

BMC Health Serv Res· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Medical outcomes associated with prescription opioid abuse via oral and non-oral routes of administration.
Jody L Green, Becki Bucher Bartelson, M Claire Le Lait, Carl L Roland, Elizabeth T Masters

Drug Alcohol Depend· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Costs and Work Loss Burden of Diagnosed Opioid Abuse Among Employees on Workers Compensation or Short-term Disability.
Stephen S Johnston, Andrea H Alexander, Elizabeth T Masters, Jack Mardekian, David Semel

J Occup Environ Med· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluating increased resource use in fibromyalgia using electronic health records.
Jay M Margolis, Elizabeth T Masters, Joseph C Cappelleri, David M Smith, Steven Faulkner

Clinicoecon Outcomes Res· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fibromyalgia Outcomes Over Time: Results from a Prospective Observational Study in the United States.
Caroline P Schaefer, Edgar H Adams, Margarita Udall, Elizabeth T Masters, Rachael M Mann

Open Rheumatol J· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Progression of fibromyalgia: results from a 2-year observational fibromyalgia and chronic pain study in the US.
Edgar H Adams, Heather J McElroy, Margarita Udall, Elizabeth T Masters, Rachael M Mann

J Pain Res· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis